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Abstract
α2-macroglobulin (α2M) is an extracellular chaperone that inhibits amorphous and fibrillar
protein aggregation. The reaction of α2M with proteases results in an “activated”
conformation, where the proteases become covalently-linked within the interior of a cage-like
structure formed by α2M. This study investigates, for the first time, the effect of activation on
the ability of α2M to inhibit amyloid formation of Aβ1-42 and I59T human lysozyme and
shows that protease-activated α2M can act via two distinct mechanisms: (i) by trapping
proteases still able to degrade polypeptide chains and (ii) by a chaperone action that prevents
misfolded clients from continuing along the amyloid forming pathway.
Keywords
α2-macroglobulin, extracellular chaperones, amyloid disease, human lysozyme, Aβ1-42

Abbreviations
α2M, α2-Macroglobulin; LRP, lipoprotein receptor-related protein; trypsin-α2M, trypsinactivated α2M; (i)trypsin-α2M, trypsin-activated α2M treated with small molecule protease
inhibitors; ThT, Thioflavin T.
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Highlights
-

α2M is an extracellular chaperone capable of inhibiting amorphous and fibrillar
protein aggregation.

-

We show that after activation of α2M by proteases, protease-α2M complexes can
inhibit amyloid formation in vitro by degrading amyloidogenic substrates or by acting
as a chaperone.

-

Inhibition of amyloid formation by activated α2M may play an important role in
preventing pathological protein deposition in vivo.
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Introduction
α2-Macroglobulin is a highly abundant glycoprotein present in blood plasma,
cerebrospinal fluid and other extracellular fluids. α2M is best known for its ability to trap a
broad range of proteases within a cage-like quaternary structure via covalent-linkage of the
protease to intramolecular thioester bonds on α2M [1]. This reaction results in a
conformationally altered form commonly known as “activated” or “fast” α2M, the latter term
relating to enhanced mobility via native gel electrophoresis. Activation of α2M results in the
exposure of a cryptic receptor recognition site for the low-density lipoprotein receptor-related
protein [1]. In addition to proteases, small nucleophiles can activate α2M by interacting
directly with its thioester bonds [2].
Along with protease trapping, many other biological functions have been proposed for
α2M; including roles in immunomodulation, cancer progression and extracellular proteostasis
[4-6]. α2M can bind to a range of endogenous disease-associated proteins including the
amyloid β peptide (Aβ1-42) [7], prion protein [8] and β2-microglobulin [9], which are the main
components of deposits found in Alzheimer’s disease (AD), spongiform encephalopathies
and dialysis-related amyloidosis, respectively [10]. Moreover, α2M is found to be colocalized in vivo with amyloid deposits in AD and the spongiform encephalopathies [8,11].
Recent work has shown that native α2M can act as an ATP-independent molecular chaperone
by suppressing stress-induced amorphous protein aggregation [6]. The mechanism by which
this occurs appears to involve the formation of stable, soluble complexes between α2M and
the misfolded client proteins [6]. Native α2M has also been shown to suppress the fibril
formation of a range of amyloidogenic proteins and peptides [12,13]. It has been proposed
that α2M can protect against pathogenic misfolded proteins by promoting their removal from
the extracellular space [7,14,15]. However, trypsin-activated α2M (trypsin-α2M) is reportedly
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unable to prevent the amorphous aggregration, in vitro, of some proteins [6]. Nevertheless,
after binding to misfolded proteins, α2M retains the ability to become activated, and α2Mtrypsin-misfolded protein complexes are recognized by LRP [6], representing a potential
route for the targeted disposal of misfolded proteins in vivo.
Activated α2M can protect cells from Aβ toxicity in vitro through specific binding
and subsequent LRP mediated uptake and degradation of Aβ [7,11,16]. While it is clear that
1−40

activated α2M can bind to Aβ peptide, its ability to prevent the fibrillar aggregation of
amyloid forming peptides or proteins has not been tested. To address this issue, we
investigate the effect of activated α2M on the fibril formation of the amyloidogenic Aβ1-42
peptide and of a non-natural variant of human lysozyme (I59T) that possesses many attributes
associated with the natural amyloidogenic variants linked to systemic amyloidosis [17].

Materials and Methods
Chemicals and reagents were purchased from Sigma-Aldrich Ltd. unless otherwise stated.
Proteins and peptides
α2M was purified from human plasma by zinc chelate affinity chromatography and size
exclusion chromatography (SEC) as previously described [6]. Purified α2M was stored at 4°C
(less than 2 months) and routinely examined by native polyacrylamide gel electrophoresis
(PAGE) to ensure that the preparation had not become partially degraded, activated or crosslinked, modifications that can occur with prolonged storage [5,18,19]. Aβ1-42 was purchased
from Biopeptide Co. Inc. or Bachem AG. Solutions of Aβ1-42 peptide were prepared by a
TFA/HFIP dissolution method [20]. The non-natural variant of human lysozyme, I59T, was
expressed and purified as previously described [17].

Preparation of activated α 2M
5

Trypsin-α2M was prepared by incubating α2M with a 3-fold molar excess of bovine trypsin
in PBS (pH 7.4, 25°C, 45 min). The degree of α2M activation was assessed by NuPAGE
Novex 3-8% Tris-acetate gels with Tris-glycine native running buffer (Life Technologies
Ltd.). The reaction was allowed to continue for up to an additional 45 min to ensure
completion. Unreacted trypsin was removed by SEC and SDS-PAGE analysis using
NuPAGE Novex 4-12% Bis-Tris gels with MES running buffer (Life Technologies Ltd.)
confirmed no cleavage outside the bait region had occurred. To produce enzymatically
inactivated trypsin-α2M (i.e. (i)trypsin-α2M), trypsin-α2M was incubated (2 h, 25°C) with
excess CompleteTM protease inhibitor cocktail (Roche Diagnostics Ltd.) and samples were
desalted using ZebaTM desalting columns (Thermo Fisher Scientific). Ammonium chloride
(NH4Cl) activation was performed by incubating α2M with 400 mM NH4Cl in PBS (14 h,
25°C) and subsequently desalting as described. 	
  
Thioflavin-T assays
Aβ1-42 (5 µM, PBS (pH 7.4), 50 µM ThT) was incubated in a 384 well plate (37°C, with
shaking) using a FLUOstar OPTIMA fluorescence plate reader (BMG Labtech Ltd.) with
excitation and emission wavelengths of 440 nm and 480 nm (slit-widths 10 nm). I59T
lysozyme (6.8 µM, 0.1 M citrate buffer (pH 5.0), 25 µM ThT) was incubated with stirring at
60°C in a Cary Eclipse spectrofluorimeter (Agilent Ltd.) and ThT fluorescence intensity was
monitored with excitation and emission wavelengths of 440 nm and 480 nm (slit widths 5
nm). All samples incubated with native α2M, trypsin-α2M, (i)trypsin-α2M, or NH4Clactivated α2M contained a molar ratio of substrate-to-α2M of 10:1, based on the molecular
weights of the α2M tetramer (720 kDa), the Aβ1-42 monomer (4.5 kDa) or the I59T monomer
(14.7 kDa). All experiments were performed in triplicate.
SDS-PAGE analysis
At the endpoint of the aggregation assays, aliquots were removed and either centrifuged (10
6

min, 10,000g) (I59T lysozyme and Aβ1-42) or filtered (0.22 µm filter) (I59T lysozyme). For
I59T lysozyme, the pellet fractions were rinsed with dH2O, centrifuged again (10 min,
10,000g) and then dissolved in 10 µL of 8M Urea solution. The supernatants and solubilised
pellets were separated on 4-12% NuPAGE gels under reducing conditions. The gels were
stained with Coomassie Brilliant Blue or Sigma ProteoSilver stain kit for I59T and Aβ1-42,
respectively. Additionally, Aβ1-42 labelled with HilyteTM 488 (AnaSpec) was incubated with
10:1 substrate-to-trypsin-α2M (30 min, 25°C) and centrifuged (10 min, 10,000g). The
supernatants were separated on 4-12% NuPAGE gels and visualized using a Typhoon Trio
Imager (GE Healthcare Ltd).
Transmission electron microscopy
Fibril samples (5 µL) were applied to carbon-coated nickel grids, stained with 2% (w/v)
uranyl acetate, and imaged on a FEI Tecnai G2 transmission electron microscope (MultiImaging Unit in the Department of Physiology, Development and Neuroscience, University
of Cambridge, UK). Images were analysed using the SIS Megaview II Image Capture system
(Olympus).
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Results
Native α2M has previously been shown to inhibit the amorphous and fibrillar
aggregation of a range of proteins by increasing their solubility [6,12,13,17]. To determine if
activated α2M can also prevent amyloid formation, we compared the effect of native α2M
and trypsin-α2M on the fibril formation of I59T lysozyme and the amyloidogenic peptide
Aβ1-42. Previously reported conditions for generating trypsin-α2M vary greatly [2,6,21],
therefore, in this study we used an optimized method to obtain preparations of trypsin-α2M
that were completely activated but not degraded (Supplementary Fig. 1). The aggregation
behavior of I59T lysozyme is well established and this system has been used to study the
effects on fibril formation of the extracellular chaperones clusterin, haptoglobin and native
α2M [13, 22]. In this study, the kinetics of the aggregation show a lag phase of ca. 50
minutes, followed by a rapid growth phase that reaches a plateau after ca. 150 minutes (Fig.
1a, black line). α2M, present at a molar ratio of 10:1 (lysozyme-to-α2M), shows a dramatic
decrease in thioflavin-T (ThT) fluorescence over the course of the assay (Fig. 1a; red line).
When trypsin-α2M is incubated with 159T lysozyme the ThT fluorescence is again,
significantly suppressed (Fig. 1a; blue line). At the endpoint of the fibril formation, the
presence of both native α2M and trypsin-α2M results in over a 90% decrease in ThT signal
relative to the I59T lysozyme sample alone (Fig. 1b).
TEM images of the ThT assay endpoint samples demonstrate that while I59T
lysozyme alone forms fibrillar structures there is no evidence for such structures when I59T
lysozyme is incubated under the same conditions with native α2M or trypsin-α2M (Fig. 1c).
SDS-PAGE analysis of the endpoint supernatants reveals that no detectable I59T lysozyme
remains in solution when incubated alone, whereas in the presence of native α2M, a large
majority (>90%) of lysozyme remains soluble (Fig. 1d). The I59T lysozyme also remains in
the soluble fraction when incubated with trypsin-α2M and shows no evidence of proteolytic
8

degradation (Fig. 1d). Conversely, the pellet fractions (solublised with 8M urea), shows a
large proportion of I59T lysozyme in the I59T alone sample (Fig. 1e, lane 1p) and only trace
amounts (less than 10%) of lysozyme present in samples incubated with native α2M and
trypsin-α2M (Fig. 1e, lane 2p & 3p). This finding is consistent with the fraction of the
maximum ThT signal observed at the aggregation endpoints (Fig. 1b). In separate
experiments, incubation of monomeric I59T lysozyme with trypsin or trypsin-α2M does not
result in the appearance of any degraded protein in the soluble fractions after 120 min of
incubation under the aggregation conditions used (Supplementary Fig. 2a), in addition,
trypsin alone has no effect on I59T fibril formation (Supplementary Fig. 2b). However, it is
noted that small quantities of protein fragments (less than 5% of total protein) are apparent in
the SDS-PAGE analysis of the pellet samples after 300 min incubation. These fragments may
be the result of residual trypsin-α2M activity, but they appear to be aggregation prone as they
are only apparent in small quantities in the insoluble pellet sample. Taken together these
results reveal that, native α2M and trypsin-α2M are able to suppress I59T fibril formation
predominantly via chaperone action.
We next evaluated whether trypsin-α2M could also suppress Aβ1-42 fibril formation.
Under the conditions used here, aggregation of Aβ1-42 shows a lag of ca. 70 minutes, followed
by a rapid growth phase and a plateau at ca. 150 minutes (Fig. 2a, black line). Consistent with
previous studies [13], the presence of native α2M at a 10:1 (Aβ1-42-to-α2M) molar ratio
dramatically reduces the time-dependent increase in ThT fluorescence (Fig. 1a; red line). At
the same molar ratio, the presence of trypsin-α2M also results in a suppression of ThT
fluorescence (Fig 2a, solid blue line). This suppression in ThT signal is over 80% for both the
presence of native α2M and trypsin-α2M at the endpoint of the assay (Fig 2b). In all samples
containing Aβ1-42 there is a small ThT fluorescence signal at the start of the assay, likely due
to some ThT positive aggregates being present in the stock peptide solutions. This level
9

remains constant over the time course for the samples containing native α2M, but decreases
slightly in the presence of trypsin-α2M. We suspect that this may be due to the ability of
trypsin-α2M to degrade these ThT positive species.
TEM images of the ThT assay endpoint samples show that fibrillar aggregates are
formed by Aβ1-42 incubated alone; however, in the presence of either native α2M or trypsinα2M, the number of well-defined fibrils is reduced and aggregates appear amorphous (Fig.
2c). Analysis of the endpoint supernatants by SDS-PAGE reveals that incubation of Aβ1-42
with trypsin-α2M results in proteolysis of the peptide (Fig. 2d, lane 3). This result is
consistent with previous work showing that α2M-trapped proteases remain active against
small substrates including Aβ1-42 [23]. Therefore, it appears that trypsin-α2M prevents Aβ1-42
fibril formation, under these conditions at least partly via degradation of the Aβ1-42 peptide to
form smaller species that remain soluble. Interestingly, this mechanism for inhibiting fibril
formation may not be restricted to just Aβ1-42. We have also observed that trypsin-α2M can
suppress the fibril formation of α-lactalbumin by a process which appears to involve
proteolysis of the full-length protein (Supplementary Fig. 3).
Given that trypsin-α2M can degrade polypeptides which can enter the activated α2M
cage, it is necessary to inactivate the bound trypsin to examine, in isolation, whether trypsinα2M possesses chaperone activity similar to native α2M. Trypsin-α2M and trypsin-α2M after
treatment with a small molecule protease inhibitor ((i)trypsin-α2M) migrate similarly when
analyzed by native PAGE, suggesting that protease inactivation does not grossly affect the
structure of the covalent complex (Supplementary Fig. 1). Incubation of fluorophore-labelled
Aβ1-42 with trypsin-α2M shows that pre-treatment of the latter with protease inhibitors
prevents detectable proteolysis of Aβ1-42 (Fig. 2e), however, the (i)trypsin-α2M retains the
ability to inhibit Aβ1-42 aggregation (Fig. 2a, blue circles). Significantly, analysis of the
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endpoint supernatants reveals that soluble, full-length Aβ1-42 is present in the (i)trypsin-α2M
sample and no degradation fragments are observed (Fig. 2d, lane 4). Analysis by TEM
confirms that no fibrils are present in the Aβ1-42 sample containing (i)trypsin-α2M (Fig. 2c).
To confirm that chaperone activity of activated α2M is not reliant on the presence of
the bound protease, we tested the ability of NH4Cl activated-α2M to suppress fibril
formation. Data from aggregation assays show that NH4Cl-activated α2M effectively
suppresses the ThT fluorescence associated with fibril formation by Aβ1-42 peptide or I59T
lysozyme (Fig. 1a and Fig. 2a, green lines). TEM images of the endpoint samples show that
only traces of fibrillar species are present in either the Aβ1-42 or the I59T sample containing
NH4Cl-activated α2M. Furthermore, SDS-PAGE analysis of the endpoint supernatants
demonstrates that the presence of NH4Cl-activated α2M increases the proportion of both
client proteins remaining in their soluble, full-length forms at the endpoint of the assays (Fig.
1d, lane 4 and Fig. 2d lane 5). These results confirm that activated α2M can influence the
solubility of polypeptides regardless of whether or not it is complexed to a protease molecule.
Discussion
In the work presented here, we show that activated α2M, despite a large
conformational change upon activation, retains the ability to suppress fibril formation. From
earlier work, it is clear that α2M has distinct binding sites for protease and misfolded proteins
as the binding of a misfolded client protein does not prevent protease trapping [7]. In the
current study, we demonstrate that the presence of bound protease, regardless of whether the
protease is pharmacologically inhibited, does not significantly reduce chaperone activity of
α2M. Moreover, α2M remains an active chaperone after direct activation using small
molecules.
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In vivo, activated α2M is rapidly cleared from circulation [2] and typically represents
only 0.17-0.7% of the total α2M in blood plasma of adults [24]. The activated α2M plasma
concentration is, however, increased in many disease states including pancreatitis, multiple
sclerosis	
   and sepsis [24-26]. Moreover, the onset of some diseases, such as periodontitis,
diabetic retinopathy and inflammatory joint disease results in increased activated α2M levels
in other extracellular fluids [27,28,29]. Although enhanced concentrations of activated α2M
have been largely attributed to increased protease trapping, it has been reported that
interaction with proteases only partially accounts for the total activated α2M present in
synovial fluid	
   [29]; higher levels of both protease-activated and amine-activated α2M may
therefore be significant for facilitating clearance of aberrant clients via LRP. Interestingly,
aggregates of Aβ1-40 and amylin have been shown to activate the plasmin protease system
[30].	
  Thus it is possible that concentrations of plasmin-activated α2M may also be increased
in response to the accumulation of misfolded proteins.
In conclusion, we provide evidence that protease-activated α2M has two distinct
mechanisms for inhibiting amyloid formation: (i) via protease-α2M-mediated degradation of
amyloidogenic substrates and (ii) by a chaperone action that prevents misfolded clients from
continuing along the amyloid forming pathway. In the absence of proteases, activated α2M is
able to inhibit fibril formation via the latter function only. It is tempting to speculate that the
chaperone activity of protease-activated α2M may target misfolded proteins to the trapped
protease, thereby providing a specific mechanism for degradation of amyloidogenic proteins
in extracellular fluids. Clearly, further studies are required to substantiate this proposition;
however, a greater understanding of the mechanisms by which α2M is able to prevent protein
aggregation and facilitate the disposal of misfolded peptide and protein molecules could, in
future, provide potential therapeutic targets for amyloidosis.

12

Acknowledgements
A.R.W is grateful for a CJ Martin Fellowship (Australian National Health and Medical
Research Council) and for a Junior Research Fellowship (Wolfson College, Cambridge).
J.J.Y is supported by a Bill Gole Fellowship (Motor Neurone Disease Research Institute of
Australia). H.E is grateful for an Australian Research Council Future Fellowship (FT11010).
This research was supported in part by the BBSRC (BB/E019927/1 (C.M.D. and J.R.K.)) and
a Wellcome Trust program grant (C.M.D).

13

References
[1] Sottrup-Jensen, L. (1989). Alpha-macroglobulins: structure, shape, and mechanism of
proteinase complex formation. J Biol Chem. 264, 11539-42.
[2] Imber, M. J. & Pizzo, S. V. (1981). Clearance and binding of two electrophoretic "fast"
forms of human alpha-2-macroglobulin. J Biol Chem. 256, 8134-9.
[3] Marrero, A., Duquerroy, S., Trapani, S., Goulas, T., Guevara, T., Andersen, G. R.,
Navaza, J., Sottrup-Jensen, L. & Gomis-Ruth, F. X. (2012). The crystal structure of human
alpha-2-macroglobulin reveals a unique molecular cage. Angew Chem. 51, 3340-3344.
[4] Armstrong, P. B. & Quigley, J. P. (1999). Alpha-2-macroglobulin: an evolutionarily
conserved arm of the innate immune system. Dev Comp Immunol. 23, 375-390.
[5] Borth, W. (1992). Alpha-2-macroglobulin, a multifunctional binding protein with
targeting characteristics. FASEB J. 6, 3345-3353.
[6] French, K., Yerbury, J. J. & Wilson, M. R. (2008). Protease activation of α2macroglobulin modulates a chaperone-like action with broad specificity. Biochemistry. 47,
1176-1185.
[7] Narita, M., Holtzman, D. M., Schwartz, A. L. & Bu, G. (1997). Alpha-2-macroglobulin
complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface lowdensity lipoprotein receptor-related protein. J Neurochem. 69, 1904-11.
[8] Adler, V. & Kryukov, V. (2007). Serum macroglobulin induces prion protein transition.
Neurochem J. 1, 43-52.
[9] Motomiya, Y., Ando, Y., Haraoka, K., Sun, X., Iwamoto, H., Uchimura, T. &
Maruyama, I. (2003). Circulating level of alpha-2-macroglobulin-beta-2-microglobulin
complex in hemodialysis patients. Kidney Int. 64, 2244-52.
[10] Chiti, F. & Dobson, C. M. (2006). Protein misfolding, functional amyloid, and human
disease. Ann Rev Biochem. 75, 333-366.
[11] Fabrizi, C., Businaro, R., Lauro, G. M. & Fumagalli, L. (2001). Role of alpha-2macroglobulin in regulating amyloid beta-protein neurotoxicity: protective or detrimental
factor? J Neurochem. 78, 406-12.
[12] Hughes, S. R., Khorkova, O., Goyal, S., Knaeblein, J., Heroux, J., Riedel, N. G. &
Sahasrabudhe, S. (1998). Alpha-2-macroglobulin associates with beta-amyloid peptide and
prevents fibril formation. Proc Natl Acad Sci USA. 95, 3275-80.
[13] Yerbury, J. J., Kumita, J. R., Meehan, S., Dobson, C. M. & Wilson, M. R. (2009).
alpha-2-Macroglobulin and haptoglobin suppress amyloid formation by interacting with
prefibrillar protein species. J Biol Chem. 284, 4246-4254.

14

[14] Du, Y., Ni, B., Glinn, M., Dodel, R. C., Bales, K. R., Zhang, Z., Hyslop, P. A. & Paul,
S. M. (1997). alpha-2-Macroglobulin as a beta-amyloid peptide-binding plasma protein. J
Neurochem. 69, 299-305.
[15] Wilson, M. R., Yerbury, J. J. & Poon, S. (2008). Potential roles of abundant
extracellular chaperones in the control of amyloid formation and toxicity. Mol Biosyst. 4, 4252.
[16] Van Uden, E., Sagara, Y., Van Uden, J., Orlando, R., Mallory, M., Rockenstein, E. &
Masliah, E. (2000). A protective role of the low density lipoprotein receptor-related protein
against amyloid beta-protein toxicity. J Biol Chem. 275, 30525-30.
[17] Hagan, C. L., Johnson, R. J., Dhulesia, A., Dumoulin, M., Dumont, J., De Genst, E.,
Christodoulou, J., Robinson, C. V., Dobson, C. M. & Kumita, J. R. (2010). A non-natural
variant of human lysozyme (I59T) mimics the in vitro behaviour of the I56T variant that is
responsible for a form of familial amyloidosis. Protein Eng Del Sel. 23, 499-506.
[18] Barrett, A. J. (1981). Alpha-2-macroglobulin. Meth Enzymol. 80, 737-54.
[19] Sottrup-Jensen, L., Hansen, H. F., Pedersen, H. S. & Kristensen, L. (1990). Localization
of epsilon-lysyl-gamma-glutamyl cross-links in five human alpha-2-macroglobulinproteinase complexes. . J Biol Chem. 265, 17727-37.
[20] Teplow, D. B. (2006). Preparation of amyloid beta-protein for structural and functional
studies. Meth Enzymol. 413, 20-33.
[21] Gonias, S. L. & Pizzo, S. V. (1983). Conformation and protease binding activity of
binary and ternary human alpha-2-macroglobulin-protease complexes. J Biol Chem. 258,
14682-14685.
[22] Kumita, J. R., Poon, S., Caddy, G. L., Hagan, C. L., Dumoulin, M., Yerbury, J. J.,
Stewart, E. M., Robinson, C. V., Wilson, M. R. & Dobson, C. M. (2007). The extracellular
chaperone clusterin potently inhibits human lysozyme amyloid formation by interacting with
prefibrillar species. J Mol Biol. 369, 157-67.
[23] Lauer, D., Reichenbach, A. & Birkenmeier, G. (2001). Alpha-2-macroglobulinmediated degradation of amyloid beta 1-42: a mechanism to enhance amyloid beta
catabolism. Exp Neurol. 167, 385-92.
[24] Banks, R. E., Evans, S. W., Van Leuven, F., Alexander, D., McMahon, M. J. &
Whicher, J. T. (1990). Measurement of the 'fast' or complexed form of alpha-2-macroglobulin
in biological fluids using a sandwich enzyme immunoassay. J Immunol Meth. 126, 13-20.
[25] Jensen, P. E., Humle Jørgensen, S., Datta, P. & Sørensen, P. S. (2004). Significantly
increased fractions of transformed to total alpha-2-macroglobulin concentrations in plasma
from patients with multiple sclerosis. Biochim Biophys Acta. 1690, 203-207.
[26] de Boer, J. P., Creasey, A. A., Chang, A., Abbink, J. J., Roem, D., Eerenberg, A. J.,
Hack, C. E. & Taylor, F. B. J. (1993). Alpha-2-macroglobulin functions as an inhibitor of

15

fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model.
Infect Immun. 61, 5035-5043.
[27] Rosin, M., Benjamin, P., Rogers, P., Gibson, M., Van Leuven, F., Johnson, N. W. &
Curtis, M. (1995). Elevated conversion of alpha-2-macroglobulin to the complexed form in
gingival crevicular fluid from adult periodontitis patients. J Periodontal Res. 30, 436-444.
[28] Sánchez, M. C., Luna, J. D., Barcelona, P. F., Gramajo, A. L., Juarez, P. C., Riera, C.
M. & Chiabrando, G. A. (2007). Effect of retinal laser photocoagulation on the activity of
metalloproteinases and the alpha-2-macroglobulin proteolytic state in the vitreous of eyes
with proliferative diabetic retinopathy. Exp Eye Res. 85, 644-650.
[29] Abbink, J. J., Kamp, A. M., Nieuwenhuys, E. J., Nuijens, J. H., Swaak, A. J. & Hack, C.
E. (1991). Predominant role of neutrophils in the inactivation of alpha-2-macroglobulin in
arthritic joints. Arthritis Rheum. 34, 1139-1150.
[30] Kranenburg, O., Bouma, B., Kroon-Batenburg, L. M., Reijerkerk, A., Wu, Y. P., Voest,
E. E. & Gebbink, M. F. (2002). Tissue-type plasminogen activator is a multiligand cross-beta
structure receptor. Curr Biol. 12, 1833-1839.

16

Figure 1: Effects of α 2M variants on I59T lysozyme fibril formation
a) In vitro fibril formation of I59T lysozyme incubated alone (black), with native α2M (red),
with trypsin-α2M (blue) or with NH4Cl-activated α2M (green) using α2M-to-lysozyme molar
ratios of 1:10. b) Percent of maximum ThT signal at the endpoint of aggregation. Each bar
represents an average of three individual experiments. c) TEM analysis of the endpoint
samples in the absence or presence of the different α2M variants, with scale bars representing
100 nm and numbering corresponds to the lanes in gel analysis. c) SDS-PAGE of the
endpoint supernatants shows no soluble protein in I59T lysozyme incubated alone (1),
whereas soluble protein is present for samples containing native α2M (2), trypsin-α2M (3)
and NH4Cl-activated α2M (4) and soluble I59T lysozyme is shown in lane S and lane M
shows molecular mass markers. d) SDS-PAGE of the solubilised endpoint pellets showing
significant protein present for I59T incubated alone (1p), and trace protein present for
samples containing native α2M (2p), trypsin-α2M (3p) and NH4Cl-activated α2M (4p).

Figure 2: Effects of α 2M variants on Aβ 1-42 fibril formation
a) In vitro fibril formation of Aβ1-42, incubated alone (black), with native α2M (red), with
trypsin-α2M (blue), with (i)trypsin-α2M (blue circles) or with NH4Cl-activated α2M (green),
using α2M-to-Aβ1-42 molar ratios of 1:10. b) Percent of maximum ThT signal at the endpoint
of aggregation. Each bar represents the average of three individual experiments. c) TEM
analysis of the endpoint samples in the absence or presence of the different α2M variants,
with scale bars representing 100 nm and and numbering corresponds to the lanes in gel
analysis. d) SDS-PAGE analysis of the endpoint supernatants shows no soluble protein for
Aβ1-42 incubated alone (1), but soluble peptide present when incubated with native α2M (2).
Incubation with trypsin-α2M (3) results in no full-length Aβ1-42 peptide, whereas the
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incubation with (i)trypsin-α2M (4) and NH4Cl-activated α2M (5) have full-length peptide
present. Lane M shows molecular mass markers. d) Fluorescence image of SDS-PAGE
analysis of HiLyte-488 labelled Aβ1-42, alone (lane 1) and after incubation with trypsin-α2M
(lane 2) or (i)trypsin-α2M (lane 3). The presence of trypsin-α2M results in an increase in Aβ142 fragments

(red arrow).
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Supplementary Figure 1: Effect of activation on the migration of α2M by native
PAGE analysis
The gel shows the migration of native α2M (lane 1), trypsin-α2M (lane 2), (i)trypsinα2M (lane 3) and NH4Cl-activated α2M (lane 4) on a 3-8% Tris-acetate gel after
electrophoresis at 150 V for 1.5 hr.
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Supplementary Figure 2:
a) SDS-PAGE analysis of I59T lysozyme samples which were incubated at 37°C or
60°C for 2 hr in the absence (lanes 1 and 4) and presence of trypsin (lanes 2 and 5)
or trypsin-α2M (lanes 3 and 6). The molar ratios of trypsin-to-I59T and trypsin-α2M-toI59T were 1:5 and 1:10 respectively. The gel was run under reducing conditions to
confirm that no degradation of full length I59T protein had occurred under either set
of conditions. b) In vitro fibril formation (60°C, pH 5.0) of I59T lysozyme (solid line) in
the absence or presence of trypsin (dashed line) at a 1:10 (trypsin-to-lysozyme)
molar ratio as monitored by light scattering. The presence of trypsin does not
significantly affect the overall fibril formation of I59T lysozyme.

500

a)

Normalised ThT Signal (480 nm)

1.2
1.0
0.8
0.6
0.4
0.2
0.0

0

200

400

600

800

1000

15 kDa

M

+n

b)

α−l

act

alo

ne

ativ
eα
2M
+ tr
yps
in-α
+p
2M
las
min
-α2
M

Time (min)

Full length α-lact

10 kDa

Supplementary Figure 3: Effects of native and trypsin- α2M on fibril formation
by α-lactalbumin
a) In vitro fibril formation (37°C, pH 7.4) of α-lactalbumin (α-lact) alone (black) or in
the presence of native α2M (red) or trypsin-α2M (blue) as monitored by ThT
fluorescence. The molar ratio of α 2M-to-α-lact used was 1:10. The experiment was
performed in triplicate. b) SDS-PAGE analysis of the endpoint samples. Some
soluble protein remains in the sample containing α-lact alone, but more full-length,
soluble α-lact is present in the sample containing native α2M. After coincubation with trypsin α 2M, SDS-PAGE analysis shows less full-length α-lact than
does a corresponding sample of α-lact after co-incubation with plasmin-α 2 M.

